Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Sigma-Aldrich Completes Acquisition of BioReliance

Published: Wednesday, February 01, 2012
Last Updated: Wednesday, February 01, 2012
Bookmark and Share
Sigma-Aldrich Corporation completes its acquisition of BioReliance Holdings, Inc. for $350 million in cash.

BioReliance provides critical services that include biologic, specialized toxicology and animal health testing to pharmaceutical, biopharmaceutical, diagnostics, and other life science customers worldwide.  As a leading provider of biological safety testing, its service offering helps facilitate the development, manufacturing and commercialization of biological drugs and helps enable its clients to register their products worldwide. As a service provider of toxicology studies, BioReliance also enables its clients to launch new small molecule drugs worldwide.  BioReliance employs over 650 people and is headquartered in Rockville, Maryland, with additional operations in Glasgow and Stirling, Scotland and sales offices in Tokyo, Japan and Bangalore, India.

"BioReliance's global biopharmaceutical testing services will enable Sigma-Aldrich to build a specialized services platform that complements our existing products and technology strengths.  It will expand our participation in the fast growing biological drug market and will help forge deeper and stronger strategic ties with existing and new customers," said Rakesh Sachdev, President and CEO.

BioReliance will become part of SAFC, the custom manufacturing and services business unit of Sigma-Aldrich. Gilles Cottier, SAFC President commented, "The combination of BioReliance and SAFC provides a richer value proposition for the development and manufacture of biological drugs. By leveraging SAFC's industrial media presence and BioReliance's biological testing services, we can provide new and better end-to-end product solutions and services to our biopharmaceutical customers. The alliance also provides an opportunity to leverage our CompoZr® zinc finger nuclease (ZFN) technology with BioReliance's Toxicology and Animal Health Services operations for the development of new assays, cell lines and animal models for the Research marketplace."

BioReliance generated revenues of approximately $110 million in the year ended December 31, 2010 with double-digit growth expected in 2011.  The acquisition is expected to be modestly accretive to Sigma-Aldrich's diluted earnings per share in 2012.  Sigma-Aldrich funded the acquisition with a combination of existing cash and credit facilities.

Cautionary statement:  The foregoing release contains forward-looking statements that can be identified by terminology such as "opportunity to leverage", "expanding", "will", "enable", "expected" and variations of such words and similar expressions, or by expressed or implied discussions regarding potential future revenues, earnings and free cash flow from the acquisition of BioReliance.  You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements.  There can be no guarantee that the acquisition of BioReliance will achieve any particular levels of revenue in the future.  In particular, management's expectations regarding the acquisition of BioReliance could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; Sigma-Aldrich's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's annual and quarterly reports on Form10-K and Form 10-Q on file with the US Securities and Exchange Commission.  Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected.  Sigma-Aldrich does not undertake any obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Sigma-Aldrich Stockholders Approve Merck Acquisition
The transaction, expected to close mid-2015, remains subject to the satisfaction of the closing conditions set forth in the merger agreement, including regulatory approvals.
Monday, December 08, 2014
SAFC Expands Continuous Flow Capabilities
Sigma-Aldrich custom manufacturing services business unit, SAFC® Commercial, has installed a new commercial-scale continuous flow reactor at its Sheboygan, WI facility.
Wednesday, May 21, 2014
Sigma-Aldrich® Partners with Scripps Research Institute
The agreement marks first partnership of its kind between a research institution and reagents company.
Friday, July 19, 2013
Sigma Life Science to Distribute Olink Bioscience's Protein-Protein Interaction Assay
The products complement Sigma's antibody, RNAi and gene editing technologies.
Tuesday, February 12, 2013
Sigma Life Science Collaborates with Cofactor Genomics to Develop Publically Available Rat Genome Database
Sigma Life Science announces that its SAGE Labs initiative has partnered with Cofactor Genomics in an effort to sequence genomes for six of the most widely used strains of rat. Cofactor Genomics plans to generate and analyze sequence data using next generation sequencing systems, while SAGE Labs plans to provide the samples and to host a new, free public database at in late 2011.
Thursday, February 03, 2011
Sigma® Life Science Awarded Silver in Top Ten Innovations 2010
Company’s CompoZr® cell lines ranked second as The Scientist magazine unveils this year’s best life science innovations.
Monday, December 06, 2010
Plasticell Signs Technology Agreement with Sigma-Aldrich
Collaboration to produce novel turnkey solution for stem cell research.
Tuesday, November 30, 2010
Sigma® Life Science Enters Genetically Modified Cell Market
Sigma Life Science launches range of engineered cell lines exploiting CompoZr® zinc finger nuclease technology.
Monday, September 06, 2010
Sigma® Life Science and Switchgear Genomics to Co-Develop Simplified Novel MicroRNA Target Validation System
SwitchGear Genomics and Sigma’s lentiviral technology combined to simplify miRNA target validation, enabling researchers to investigate gene regulation.
Tuesday, August 10, 2010
Sigma-Aldrich Licenses from NeuroSurvival Technologies a Marker for Molecular Imaging of Apoptosis in Vivo
The marker, Apo-TRACE™, offers a breakthrough in advancing apoptosis-related research in a range of fields in biology and medicine.
Wednesday, February 27, 2008
Sigma-Aldrich Grants Pfizer Non-Exclusive Worldwide License to Use ddRNAi in Research Programs
The license enables Pfizer to undertake research activities throughout its global operations using ddRNAi technology.
Thursday, January 04, 2007
Sigma-Proligo Expands into Genopole® d'Evry Biopark
Sigma-Proligo provides researchers with high-quality oligonucleotides due to a high throughput synthesis platform.
Friday, October 20, 2006
Sigma-Aldrich Announces Service Provider for WGA Technology
Sigma announces MOgene as its first service provider of the GenomePlex® Whole Genome Amplification technology.
Wednesday, May 31, 2006
Sigma-Aldrich Sponsors Full-Text Article on High Content Viral Library Screens
The authors reported the creation of a lentiviral shRNA library to knock down genes for genome-wide screening.
Thursday, April 27, 2006
Scientists Publish Results on Sigma-Aldrich's shRNA Library in Cell
The publication reported the creation of a lentiviral shRNA library to knock down genes for genome-wide screening.
Thursday, April 13, 2006
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Chromosomal Chaos
Penn study forms basis for future precision medicine approaches for Sezary syndrome
Enzyme Malfunction May be Why Binge Drinking Can Lead to Alcoholism
A new study in mice shows that restoring the synthesis of a key brain chemical tied to inhibiting addictive behavior may help prevent alcohol cravings following binge drinking.
Key to Natural Detoxifier’s Reactivity Discovered
Results have implications for health, drug design and chemical synthesis.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
New Protein Found in Immune Cells
Immunobiologists from the University of Freiburg discover Kidins220/ARMS in B cells and demonstrate its functions.
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Shaking Up the Foundations of Epigenetics
Researchers at the Centre for Genomic Regulation (CRG) and the University of Barcelona (UB) published a study that challenges some of the current beliefs about epigenetics.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos